
Profile
General Information
Lescol has been approved for a new indication--a treatment to decrease the progression of coronary atherosclerosis in patients with coronary heart disease undergoing treatment programs to lower lipoprotein cholesterol. Lescol was originally approved in 1994 for patients with primary hypercholesterolemia.
Approval Date: 1997-09-01
Company Name: Novartis